WHO resumes Sputnik V vaccine review process – news

The World Health Organization (WHO) said on Thursday it would resume vaccine reviewa Sputnik V coNTra the coronavirus, an obligation to be part of the inoculants authorized for international travel and for the international Covax system to distribute them.

WHO Deputy Director-General for Access to Medicines, Mariangela Simao, said that, After stopping the evaluation through legal procedures, the international organization and the Russian government are moving forward again with the “emergency” approval of the drug developed by the National Center for Epidemiology and Microbiology in Gamaleya..

“I am happy to report that in the discussions we are having with the Russian government, this problem has not yet been resolved and as soon as these processes are completed we will be able to resume the proceedings,” Simao said during of a press conference. , according to the media. Moscow time.

/ Home Integration code /

/ End of integration code /

The announcement comes nearly a week after Russian Health Minister Mikhail Murashko said after a meeting with WHO chief Tedros Adhanom Gebreyesus that “all obstacles have been raised “to the recognition of the immunizing Sputnik.

On another side, Russia has indicated that it will locate 50% of production of this vaccine for next month at foreign facilities.

“By November, more than 50% of Sputnik V and Sputnik Light will be produced outside of Russia,” Russian Direct Investment Fund (RDIF) director Kiril Dmitriev told Bloomberg Invest Global , quoted by the Sputnik News Agency.

Until the date, WHO has included Moderna, Pfizer / BioNTech, Johnson & Johnson and the two versions of AstraZeneca in the list of drugs approved for emergency use., the one made in India (called Covishield) and the one it is developing in South Korea.

It also granted this authorization to those of Chinese origin from Sinovac (called CoronaVac) and Sinopharm.

/ Home Integration code /

/ Complete the embed code /

Sputnik has been administered extensively in Russia, where relevant entities have approved its use, as well as in several Latin American countries.

Sputnik light, which is the first component of Sputnik V, has an efficiency between 78% and 83%, according to data from the Ministry of Health of the Province of Buenos Aires.